NRIX Key Statistics, Chart & Performance
The current stock price of NRIX is 18.09 USD. In the past month the price increased by 44.49%. In the past year, price decreased by -15.35%.
NRIX Latest News, Press Relases and Analysis
NRIX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About NRIX
Company Profile
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 286 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The firm is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
Company Info
NURIX THERAPEUTICS INC
1700 Owens St Ste 205
San Francisco CALIFORNIA 94158 US
CEO: Arthur T. Sands
Employees: 286
Phone: 14156605320
NURIX THERAPEUTICS INC / NRIX FAQ
What does NURIX THERAPEUTICS INC do?
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 286 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The firm is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
Can you provide the latest stock price for NURIX THERAPEUTICS INC?
The current stock price of NRIX is 18.09 USD. The price increased by 0.39% in the last trading session.
Does NURIX THERAPEUTICS INC pay dividends?
NRIX does not pay a dividend.
What is the ChartMill technical and fundamental rating of NRIX stock?
NRIX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the next earnings date for NRIX stock?
NURIX THERAPEUTICS INC (NRIX) will report earnings on 2026-01-26, after the market close.
Who owns NURIX THERAPEUTICS INC?
You can find the ownership structure of NURIX THERAPEUTICS INC (NRIX) on the Ownership tab.
What is the outstanding short interest for NURIX THERAPEUTICS INC?
The outstanding short interest for NURIX THERAPEUTICS INC (NRIX) is 14.31% of its float.
NRIX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NRIX. When comparing the yearly performance of all stocks, NRIX is one of the better performing stocks in the market, outperforming 90.09% of all stocks.
NRIX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NRIX. No worries on liquidiy or solvency for NRIX as it has an excellent financial health rating, but there are worries on the profitability.
NRIX Financial Highlights
Over the last trailing twelve months NRIX reported a non-GAAP Earnings per Share(EPS) of -2.97. The EPS decreased by -2.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.85% | ||
| ROE | -65.76% | ||
| Debt/Equity | 0 |
NRIX Forecast & Estimates
23 analysts have analysed NRIX and the average price target is 27.72 USD. This implies a price increase of 53.23% is expected in the next year compared to the current price of 18.09.
For the next year, analysts expect an EPS growth of -11.13% and a revenue growth 55.1% for NRIX